Stocks · Healthcare · Medical - Instruments & Supplies
BioLife Solutions, Inc. BLFS
$37.30 +1.41% Close, Oct 2, 2026 · NASDAQ · Market cap $1.82B
Strong trendLow risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 7.2% from -23.6% a year earlier.
- Revenue over the last four quarters was $102.8M, up 34.4% from a year earlier, slowing from 40.9% a quarter earlier.
- The stock is in an uptrend: above its 200-day average for 94 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth29Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 23%
- FCF growth (TTM, YoY)Bottom 13%
- Revenue growth, 3-year CAGRBottom 44%
- Revenue growth accelerationBottom 22%
Quality66Positive
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 30%
- Gross marginBottom 50%
- Operating marginTop 32%
- Cash conversion (OCF / net income)Bottom 11%
- Accruals (lower is better)Bottom 9%
- Net debt / EBITDA (lower is better)Top 21%
- Interest coverTop 15%
Value61Neutral
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 20%
- Free-cash-flow yieldTop 36%
- EBITDA / enterprise valueTop 36%
- Sales / enterprise valueBottom 22%
Momentum90Exceptional
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 40%
- 6-month returnTop 10%
- 1-year return vs S&P 500Top 29%
- Distance from 52-week highTop 8%
- Trend checklist (0–4)Top 7%
Revisions60Neutral
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 19%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetBottom 4%
Stability83Strong
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 15%
- Maximum drawdown, 3 yearsTop 11%
- Beta vs S&P 500 (lower is better)Bottom 34%
- Net debt / EBITDA (lower is better)Top 21%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 40.9% | 34.4% | ↓ |
| Gross margin | 81.4% | 64.5% | ↓ |
| Operating margin | -23.6% | 7.2% | ↑ |
| FCF margin | 15.0% | -0.9% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 34.4% | 40.9% | ↓ | Top 23% |
| Gross margin | 64.5% | 81.4% | ↓ | Bottom 50% |
| Operating margin | 7.2% | -23.6% | ↑ | Top 32% |
| Net margin | 49.1% | -7.2% | ↑ | — |
| Free-cash-flow margin | -0.9% | 15.0% | ↓ | — |
| Return on invested capital | 1.7% | — | Top 30% | |
| Revenue growth, 3-year CAGR | 8.1% | — | Bottom 44% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.33×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 7.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 12.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -28.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.84×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 11.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.00%
- Shareholder yield
- 0.00%
- Share count change, 1 year
- +3.1%
- Share count change, 3-year CAGR
- +4.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 4
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +1.1%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $31.00
- Target vs current price
- -16.9%
- Analysts with a rating
- 18
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +2812.0% | +0.4% | +3.5% | +6.3% | — |
| May 7, 2026 | +300.0% | +6.3% | -2.7% | +24.6% | +47.8% |
| Feb 26, 2026 | +300.0% | +0.0% | -8.0% | -11.6% | +10.1% |
| Nov 6, 2025 | +1900.0% | -2.0% | -6.0% | -6.3% | -17.2% |
| Aug 7, 2025 | -1550.0% | -2.1% | +21.8% | +22.7% | +27.5% |
| May 8, 2025 | +233.3% | +4.8% | +3.3% | +0.7% | -2.1% |
| Mar 3, 2025 | +83.3% | +2.1% | +7.6% | +8.2% | -7.2% |
| Nov 12, 2024 | +77.8% | -0.4% | -23.0% | -1.5% | -2.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $0.91 | $0.03 | +2812.0% | $28.5M |
| May 7, 2026 | $0.04 | $0.01 | +300.0% | $27.5M |
| Feb 26, 2026 | $0.04 | -$0.02 | +300.0% | $24.8M |
| Nov 6, 2025 | $0.04 | $0.00 | +1900.0% | $28.1M |
| Aug 7, 2025 | -$0.33 | -$0.02 | -1550.0% | $25.4M |
| May 8, 2025 | $0.04 | -$0.03 | +233.3% | $23.9M |
| Mar 3, 2025 | -$0.01 | -$0.06 | +83.3% | $22.7M |
| Nov 12, 2024 | -$0.02 | -$0.09 | +77.8% | $30.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 36.4× | — | — | Top 20% |
| P/E (forward) | 62.2× | — | — | — |
| EV / EBITDA | 185.5× | — | — | Top 36% |
| EV / Sales | 17.64× | — | — | Bottom 22% |
| Free-cash-flow yield | -0.05% | — | — | Top 36% |
| Earnings yield | 2.74% | — | — | Top 20% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 108
- Days above the 200-day average
- 94
- 50-day average slope (20 days)
- +10.2%
- 200-day average slope (20 days)
- +4.6%
- Distance from 50-day average
- +5.0%
- Distance from 200-day average
- +40.5%
- RSI (14)
- 53.5
- Relative volume
- 3.14×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 34.4%
- Volatility vs own 5-year history
- 1th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.42
- Correlation with S&P 500
- 0.44
- Current drawdown from 1-year high
- -4.9%
- Maximum drawdown, 3 years
- -37.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 1, 2021 | Oct 30, 2023 | -85.1% | 543 days | Not yet recovered |
| Dec 22, 2020 | May 4, 2021 | -35.5% | 90 days | 43 days (Jul 6, 2021) |
| Jul 12, 2021 | Jul 15, 2021 | -10.3% | 3 days | 12 days (Aug 2, 2021) |
| Aug 9, 2021 | Aug 18, 2021 | -10.3% | 7 days | 5 days (Aug 25, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.82B
- P/E (TTM)
- 36.4
- EPS, diluted (TTM)
- $1.02
- Revenue (TTM)
- $102.8M
- 52-week range
- $17.86 – $39.76
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $119.2M | $76.2M | $68.0M | $82.3M | $96.2M |
| Gross profit | $37.0M | $46.9M | $41.3M | $53.7M | $62.1M |
| Operating income | -$30.6M | -$5.9M | -$19.4M | -$7.1M | -$1.1M |
| Net income | -$8.9M | -$139.8M | -$68.0M | -$20.2M | -$12.1M |
| EPS (diluted) | -$0.22 | -$3.29 | -$1.55 | -$0.44 | -$0.25 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.6M | -$3.4M | $23.9M | $25.4M | $28.1M | $18.8M | $27.5M | $28.5M |
| Net income | -$1.7M | $12.5M | -$448,000 | -$15.8M | $621,000 | $3.5M | $1.2M | $45.1M |
| EPS (diluted) | -$0.04 | $0.26 | -$0.01 | -$0.33 | $0.01 | $0.08 | $0.02 | $0.91 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$4.8M | -$8.5M | -$12.5M | $8.4M | $20.1M |
| Capital expenditure | -$8.4M | -$10.4M | -$6.4M | -$3.2M | -$19.7M |
| Free cash flow | -$13.2M | -$18.9M | -$18.9M | $5.2M | $416,000 |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $1.3M | $192,000 | $10.2M | $202,000 | $18,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $82.4M
- Total assets
- $447.5M
- Total liabilities
- $27.5M
- Total debt
- $15.7M
- Net debt
- -$8.3M
- Shareholders’ equity
- $420.0M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 3,884,193
- Days to cover
- 4.49
- Change vs previous report
- -1.1%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jan 29, 2014
- 1-for-14
- Jun 16, 2000
- 1-for-5